Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients

Japanese Journal of Clinical Oncology

Volumn 41, Issue 12, 2011, Pages 1366-1372

  Hata, Akito ^a   Katakami, Nobuyuki ^a   Kunimasa, Kei ^b   Yoshioka, Hiroshige ^b   Fujita, Shiro ^a   Kaji, Reiko ^a   Tachikawa, Ryo ^c   Tomii, Keisuke ^c   Imai, Yukihiro ^a   Iwasaku, Masahiro ^b   Ishida, Tadashi ^b  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

^c KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

Erlotinib; Interstitial lung disease; Rash; Squamous cell carcinoma

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; NAVELBINE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASE REPORT; DIARRHEA; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; FATIGUE; FEMALE; GENE MUTATION; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; JAPANESE; LIVER DYSFUNCTION; LUNG SQUAMOUS CELL CARCINOMA; MALE; OVERALL SURVIVAL; RASH; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FEMALE; HUMANS; JAPAN; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SMOKING; SURVIVAL ANALYSIS;

EID: 82955229588     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr159     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Azzoli CG, Baker S, Jr, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66.
3. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
7. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
8. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
9. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
10. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non small-cell lung cancer: results from a randomised, placebo-controlled, multicenter study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
11. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
12. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
13. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
14. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
15. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-21.
17. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276-82.
18. Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, et al. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol 2010;5:99-104.
19. Matsuura S, Inui N, Ozawa Y, Nakamura Y, Toyoshima M, Yasuda K, et al. Phase II Study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations. Jpn J Clin Oncol 2011;41: 959-63.
20. Mok T, Wu YL, Au JS, Zhou C, Zhang L, Perng RP, et al. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:1609-15.
21. Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010;5:1616-22.
22. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244-52.
23. Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, et al. The efficacy of gefitinib for non-adeno non-small-cell lung cancer patients harboring EGFR mutations: a pooled analysis of published reports. Cancer Sci 2011;102:1032-7.
24. Travis WD, Rekhtman N, Riley GJ, Geisinger KR, Asamura H, Brambilla E, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010;5:411-4.
25. Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K, et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008;3:1439-45.
26. Takahashi T, Yamamoto N, Nukiwa T, Mori K, Tsuboi M, Horai T, et al. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res 2010;30:557-63.
27. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008;177:1348-57.
28. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13: 3913-21.